Invesco BulletShares 2021 High Yield Corporate Bon (BSJL) Quote

Would make a great reverse merger

$TNON****$126.32 CENTS*****CLOSED PRICE LAST NIGHT **$4.40

Keep loading! Buy all you can! 😂😂

Not many shares outstanding

Management make us happy and give us some news

TMaga, I see this as a gift that I'm taking after owning HCMC stock for over 3 years and watching it see saw. My sights are on this new company and I'm putting the old HCMC on the shelf. If by some strike of luck there is a positive outcome to the lawsuit I'll consider that another gift. I'm not co

Those who sold at 0.0001 will be upset, sure, hardly any volume

Mike DeWine is getting what he asked for, does he care? Probably not.

TGGI

INDR

Against the law not to give news when it is significant and even not so

Good things come to those who wait

0H w0w, going to $20 S00N now!✅ $DBMM UCLA✅ Xerox|Maybach|HR0wen| Savills|AbbeyRoadInst|Santander|Mercedes|Chatsworth|Ernst&Young|Omnisport|PinsentMasons


Facts and Data Speak for Themselves.
Source: https://investorshub.advfn.com/boards/read_msg.aspx?me

$TNON hit 120$ this morning

Watch the vid

Can you read L2? $ZHUD

Interesting (mostly RFK):

https://rumble.com/v5eofx9-rfk-jr.-and-vivek-rip-into-kamala-harris-for-threatening-elon-musk.html?e9s=src_v1_mfp

Of course it is.

It is easy, level two and Time And Sales, real time.

Interactive Brokers

Air Force Lieutenant missing for nearly 80 years laid to rest at Jacksonville National Cemetery

https://www.actionnewsjax.com/news/local/air-force-lieutenant-missing-nearly-80-years-laid-rest-jacksonville-national-cemetery/PTN55UZF6RGSPIKCI3GVPFAKKU/?utm_campaign=trueanthem&utm_medium

Hmmm ... .018 on the doorstep! That means we'll be losing a shareholder! Adios, bytch! The fun is just beginning!

“Excellent!”, Mr Burns

multiple amendments to the protocol
Amending SAP is allowed according to FDA regulation
to allow cross over from placebo to DCVax-L
which is the ethical thing todo and permitted by the FDA, hack probably on the instructions of the FDA change in the primary endpoint
a